Sio Gene Therapies

Sio Gene Therapies, Inc. is a clinical-stage gene therapy company focused on developing various products to combat debilitating neurodegenerative diseases. The company's pipeline includes: 1. The AXO-Lenti-PD program for the treatment of Parkinson's disease; 2. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; 3. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. Founded in 2014 by former hedge fund analyst Vivek Ramaswamy, Sio Gene Therapies, Inc. is a wholly-owned subsidiary of Roivant Sciences. On November 13, 2020, Axovant Gene Therapies Ltd. changed its name to Sio Gene Therapies, Inc., with its stock ticker symbol changing from "AXGT" to "SIOX," effective at the market open on November 13, 2020.